Pfizer, Bristol finalize deal on metabolic drugs
NEW YORK Aug 27 (Reuters) - Pfizer Inc. (PFE.N) and Bristol-Myers Squibb Co. (BMY.N) said on Monday they finalized an agreement reached in April, under which the drugmakers will research, develop and sell a class of medicines called DGAT-1 inhibitors.
The compounds could potentially treat metabolic disorders such as obesity and diabetes, the companies said. Pfizer had already discovered some such compounds in pre-clinical research, meaning early-stage studies not yet involving human subjects.
The partnership also includes DGAT-1 inhibitors that Pfizer licensed last year from German drugmaker Bayer AG BAYG.DE, including a pre-clinical compound known as PF-04415060, or BAY 74-4113.
As previously announced, Pfizer will be responsible for all early-stage studies under the Bristol-Myers deal, while the companies will jointly conduct Phase III -- or late-stage -- trials.
The companies said the compounds are designed to block DGAT-1, an enzyme that plays a big role in creation of blood fats called triglycerides which at high levels can make people more prone to diabetes and related problems.
((Reporting by Ransdell Pierson; Editing by Derek Caney; Reuters Messaging: firstname.lastname@example.org; 646-223-6034; email@example.com)) Keywords: PFIZER BRISTOLMYERS/
(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nN27435637